Budesonide
- TRADE NAMES: Pulmicort Turbuhaler (AstraZeneca); Rhinocort (AstraZeneca); Symbicort (AstraZeneca)
- INDICATIONS: Asthma, rhinitis
- CLASS: Corticosteroid / Glucocorticoid, Corticosteroid, inhaled
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Boceprevir, Efavirenz, Itraconazole, Ketoconazole, Live vaccines, Oral Contraceptives, Telaprevir
PREGNANCY CATEGORY: C
Investigated for treating COVID-19.
Budesonide–MMX is an oral formulation of budesonide that uses Multi-Matrix System (MMX) technology to extend release to the colon.
Symbicort is budesonide and formoterol.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tabs (above) to see reviews of budesonide–MMX in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/18/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric